Multiple predictive biomarkers of ICI response have been described, including CD8+ tumor-infiltrating hymphocytes (3, 4), PD-L1 expression (5, 6), tumor mutation burden (TMB; refs. 7, 8), and HLA class I haplotype (9). This evidence concerns the gene CD8A and neoplasm.